Whole Brain Radiation Therapy

RADIATION12 trials

Sponsors

H. Lee Moffitt Cancer Center and Research Institute, M.D. Anderson Cancer Center, Radiation Therapy Oncology Group, AbbVie (prior sponsor, Abbott), NRG Oncology

Conditions

Brain CancerBrain DiseasesBrain MetastasesBrain Metastases From Non-small Cell Lung CancerBrain Metastases, AdultBrain NeoplasmsCentral Nervous System DiseasesCognitive Impairment

Phase 1

Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases

TerminatedNCT00437957

H. Lee Moffitt Cancer Center and Research InstituteBrain Metastases

Start: 2006-12-31End: 2009-04-30Updated: 2017-02-23

A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases

CompletedNCT00649207

AbbVie (prior sponsor, Abbott)Brain Diseases, Brain Neoplasms, Central Nervous System Diseases +2

Start: 2008-03-31End: 2013-03-31Updated: 2017-11-21

Radiosensitization of Multiple Brain Metastases Using AGuIX Gadolinium Based Nanoparticles

CompletedNCT02820454

University Hospital, GrenobleBrain Metastases

Start: 2016-03-31End: 2019-02-28Updated: 2019-06-07

A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy

TerminatedNCT03608020

BioMimetix JV, LLCMultiple Brain Metastases

Start: 2018-10-04End: 2024-04-15Updated: 2024-04-18

Phase 2

Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer

CompletedNCT01657799

AbbVie (prior sponsor, Abbott)Brain Metastases From Non-small Cell Lung Cancer

Start: 2012-10-19End: 2015-01-22Updated: 2018-06-06

Radiotherapy of Multiple Brain Metastases Using AGuIX®

University Hospital, GrenobleBrain Metastases, Adult, Radiotherapy

Start: 2019-03-26End: 2025-03-26Target: 100Updated: 2024-06-14

Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain

CompletedNCT03898908

Grupo Español Multidisciplinar de MelanomaBrain Metastases, Metastatic Melanoma

Start: 2019-07-18End: 2023-07-31Updated: 2025-05-21

Phase 3

Randomized Trial Comparing Radiosurgery With vs Without Whole Brain Radiotherapy

CompletedNCT00548756

M.D. Anderson Cancer CenterBrain Cancer

Start: 2001-01-02End: 2023-06-02Target: 152Updated: 2023-06-07

Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors

CompletedNCT00566852

Radiation Therapy Oncology GroupCognitive/Functional Effects, Metastatic Cancer, Neurotoxicity +1

Start: 2008-03-31End: 2016-12-31Updated: 2017-08-21

Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases

CompletedNCT02360215

NRG OncologyCognitive Impairment, Metastatic Malignant Neoplasm in the Brain, Solid Neoplasm

Start: 2015-07-31End: 2019-08-26Updated: 2025-04-23

Unknown Phase

Cognitive Outcome After SRS or WBRT in Patients With Multiple Brain Metastases (CAR-Study B)

Elisabeth-TweeSteden ZiekenhuisNeoplasm Metastasis

Start: 2016-02-29End: 2023-12-31Updated: 2023-09-13

Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

RecruitingNCT03223922

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBrain Metastases

Start: 2017-07-19End: 2030-12-31Target: 24Updated: 2025-07-03

Related Papers

NANO-GBM trial of AGuIX nanoparticles with radiotherapy and temozolomide in the treatment of newly diagnosed Glioblastoma: Phase 1b outcomes and MRI-based biodistribution.

2024-07-319 citations

Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol)

BMC Cancer2023-04-1549 citations

P01.06.B Interim results from CAR-Study B: An ongoing randomized trial on the effect of SRS or WBRT on cognitive performance in patients with 11-20 brain metastases

Neuro-Oncology2022-09-013 citations

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With<i>BRAF</i>V600–Mutant Melanoma

Journal of Clinical Oncology2022-07-21173 citations

TRLS-10. MITIGATING NEUROCOGNITIVE DEFICITS FROM WHOLE-BRAIN RADIOTHERAPY IN PATIENTS WITH NUMEROUS BRAIN METASTASES VIA A NOVEL SUPEROXIDE DISMUTASE MIMETIC: RATIONALE & DESIGN OF A CLINICAL TRIAL

Neuro-Oncology Advances2019-08-01

NRG Oncology CC001: A phase III trial of hippocampal avoidance (HA) in addition to whole-brain radiotherapy (WBRT) plus memantine to preserve neurocognitive function (NCF) in patients with brain metastases (BM).

Journal of Clinical Oncology2019-05-2040 citations

Treatment of multiple brain metastases using gadolinium nanoparticles and radiotherapy: NANO-RAD, a phase I study protocol

BMJ Open2019-02-01131 citations

Quality assurance analysis of hippocampal avoidance in a melanoma whole brain radiotherapy randomized trial shows good compliance.

2018-07-205 citations

Impact of apolipoprotein E (APOE) genotype on neurocognitive function (NCF) in patients with brain metastasis (BM): An analysis of NRG Oncology’s RTOG 0614.

Journal of Clinical Oncology2018-05-205 citations

A randomised trial to compare cognitive outcome after gamma knife radiosurgery versus whole brain radiation therapy in patients with multiple brain metastases: research protocol CAR-study B.

2018-02-219 citations

Results of a randomized, global, multi-center study of whole-brain radiation therapy (WBRT) plus veliparib or placebo in patients (pts) with brain metastases (BM) from non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2015-05-205 citations

Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.

2009-10-021727 citations